Skip to main content
. 2020 Aug 15;17(3):768–781. doi: 10.20892/j.issn.2095-3941.2020.0121

Figure 3.

Figure 3

Meta-analysis of the association between PD-L1 expression and KRAS or ALK mutation status in non-small-cell lung cancer (NSCLC) patients. (A) A forest plot of studies evaluating PD-L1 expression between KRAS wild-type and KRAS mutation patients. Pooled odds ratios of KRAS group analysis were computed using a random-effects model. (B) A forest plot of studies evaluating PD-L1 expression between ALK wild-type and ALK fusion patients. Pooled odds ratios of ALK group analyses were computed using a fixed-effects model. CI, confidence interval.